At that time, Moderna revealed its strategy for using mRNA to combat cancer and rare diseases. It's 

On June 16, Moderna announced major news regarding one of its most highly anticipated follow-up prod

Betting against Palantir, Rocket Lab and Strategy was June's smartest move — leveraged short fun

Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines

Moderna, Inc.  (NASDAQ:MRNA) shares are trading higher on Monday. This follows Friday's gain of more

A classic 'flag' pattern has formed on the chart of Moderna (MRNA). This continuation patter

Moderna Inc. (MRNA) shares surged nearly 10% on Friday, extending a powerful rally that has lifted t

Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D

Piper Sandler analyst Edward Tenthoff maintains Moderna (NASDAQ:MRNA) with a Overweight and raise

Semiconductors cratered Friday, dragging the stock market lower, while health care and software led

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon tr

Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy pr

Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected f

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - Investorideas.co

It's not just a "pandemic stock," after all.

Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Hori

Provides broad overview of Company's research and early development programs expected to continu

Provides broad overview of Company's research and early development programs expected to continue to

Moderna’s experimental flu vaccine won unanimous FDA panel backing ahead of an Aug. 5 decision.

FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026CAMBRIDGE, MA / ACCESS Ne

Moderna shares have surged nearly 30% in five days, ahead of a key FDA advisory vote on its flu vacc

https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-advisers-vote-favor-modernas-flu-

Moderna flu vaccine faces a key FDA advisory panel review as analysts weigh approval odds, postmarke

Major U.S. indexes closed mixed on Tuesday, with the Dow Jones Industrial Average gaining 0.6% to 51

Financials and utilities led Wall Street higher Tuesday as oil slid toward $77 and investors brace f

Moderna expands leadership roles and commercial operations as it prepares for multiple vaccine launc

Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to support its short- and

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk

B of A Securities analyst Dimple Gosai maintains Moderna (NASDAQ:MRNA) with a Underperform and ra

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/

Moderna reports five-year melanoma trial results with Merck and expands its Ebola vaccine partnershi

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study,

Moderna, Inc. (NASDAQ:MRNA) today announced an expanded collaboration with the Coalition for Epidemi

FDA to review Moderna's experimental mRNA flu shot on June 18 as the agency signals a more trans

https://www.bloomberg.com/news/articles/2026-05-21/fda-plans-rare-advisory-hearing-to-debate-moderna

https://www.cdc.gov/ebola/situation-summary/index.html

Moderna and Novavax stocks climb as investors digest new cases in the hantavirus outbreak.

Moderna shares are trading higher in Monday's pre-market as focus shifted to a hantavirus outbre

Editor’s Note: The future prices of benchmark tracking ETFs and the headline were updated in the sto

DGXX up 19.5% in pre-market trading after increasing the offering program. EZGO, HPAI, MRAM, NVEC,

Moderna is researching hantavirus vaccine with U.S. Army while Novavax stock rises due to increased

Moderna Inc (NASDAQ: MRNA) shares are trading higher Friday morning as traders react to peer reviewe

Moderna, Inc. (NASDAQ:MRNA) shares initially surged Thursday, but have since retreated after the com

Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approv

https://www.nytimes.com/2026/05/05/us/politics/fda-covid-vaccine-studies.html

UBS analyst Eliana Merle maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price targ

Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises t

Evercore ISI Group analyst Cory Kasimov maintains Moderna (NASDAQ:MRNA) with a In-Line and raises

RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Sector Perform and raises th

MRNA revenue hits $389M, beating Wall Street estimates. Despite a Q1 loss, Moderna eyes 10% growth a